Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells.

BACKGROUND Tenascin-C (TNC) is an extracellular matrix glycoprotein, usually derived from myofibroblasts in the cancer microenvironment. Recently, however, the significance of tumor-derived TNC in initiation of cancer metastasis was disclosed. We investigated the clinical significance of cancer-derived TNC in colorectal cancer (CRC) cases. MATERIALS AND METHODS TNC expression in 170 cases of CRC was analyzed by quantitative real-time polymerase chain reaction (PCR). In addition, gene expression arrays using purely-separated cancer tissues of another 86 cases was performed and the functional implications of cancer-specific TNC were investigated. RESULTS The expression of TNC mRNA was significantly higher in CRC tissues than in the corresponding normal tissues. Cancer cell-specific TNC expression was a significant prognostic factor in CRC cases. Moreover, cancer cell-derived TNC was associated with the epithelial-mesenchymal transition (EMT) signature. CONCLUSION Cancer cell-derived TNC promotes cancer invasiveness via EMT regulation, and not cancer tissue TNC but cancer cell-specific TNC is a novel indicator of poor prognosis.

[1]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[2]  J. Brugge,et al.  Outgrowth of Single Oncogene-expressing Cells from Suppressive Epithelial Environments , 2012, Nature.

[3]  Edi Brogi,et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs , 2011, Nature Medicine.

[4]  Toshimichi Yoshida,et al.  Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. , 2011, The American journal of pathology.

[5]  Christian Pilarsky,et al.  An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types , 2009, Journal of Molecular Medicine.

[6]  K. Nakai,et al.  PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.

[7]  S. Nordling,et al.  Tenascin-C Expression and Its Prognostic Significance in Colorectal Cancer , 2008, Oncology.

[8]  R. Chiquet‐Ehrismann,et al.  Tenascin-C induced signaling in cancer. , 2006, Cancer letters.

[9]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[10]  T. Hanai,et al.  Global analysis of altered gene expressions during the process of esophageal squamous cell carcinogenesis in the rat: a study combined with a laser microdissection and a cDNA microarray. , 2005, Cancer research.

[11]  E. Bruyneel,et al.  Tenascin‐C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  M. Jinnin,et al.  Tenascin-C upregulation by transforming growth factor-β in human dermal fibroblasts involves Smad3, Sp1, and Ets1 , 2004, Oncogene.

[13]  Matthias Chiquet,et al.  Tenascins: regulation and putative functions during pathological stress , 2003, The Journal of pathology.

[14]  John Quackenbush.  Microarray data normalization and transformation , 2002, Nature Genetics.

[15]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[16]  P. Jones,et al.  The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[17]  P. Möller,et al.  Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa. , 1997, Anticancer research.

[18]  K. Winterhalter,et al.  Binding of contactin/F11 to the fibronectin type III domains 5 and 6 of tenascin is inhibited by heparin , 1996, FEBS letters.

[19]  L. Zardi,et al.  Different Susceptibility of Small and Large Human Tenascin-C Isoforms to Degradation by Matrix Metalloproteinases (*) , 1995, The Journal of Biological Chemistry.

[20]  H. Erickson,et al.  Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C , 1994, The Journal of cell biology.

[21]  G. Edelman,et al.  Multiple integrins mediate cell attachment to cytotactin/tenascin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Bhattacharyya,et al.  Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. , 1991, Human pathology.

[23]  J. Barciszewski,et al.  Analysis of structure and function of tenascin-C. , 2006, The international journal of biochemistry & cell biology.

[24]  H. Erickson,et al.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. , 1989, Annual review of cell biology.